Literature DB >> 11956074

Acceleration of G(1) cooperates with core binding factor beta-smooth muscle myosin heavy chain to induce acute leukemia in mice.

Yandan Yang1, Weihua Wang, Rebecca Cleaves, Marianna Zahurak, Linzhao Cheng, Curt I Civin, Alan D Friedman.   

Abstract

The genes encoding the AML1 (RUNX1) or CBFbeta subunits of core binding factor (CBF) are commonly altered by translocation or mutation in human leukemias. Because CBF oncoproteins slow G(1), we sought to determine whether mutations that accelerate G(1) potentiate their ability to induce transformation. Wild-type or p16(INK4a)p19(ARF) (-/-) marrow cells transduced with CBFbeta-smooth muscle myosin heavy chain (SMMHC) were transplanted into wild-type, syngeneic recipients. CBFbeta-SMMHC significantly increased the development of acute leukemias from marrow lacking the overlapping p16p19 genes, based on analysis of Kaplan-Meier event-time distributions. Wild-type marrow was also transduced with vectors expressing either E7 alone or both E7 and CBFbeta-SMMHC. Combining oncogenes again increased leukemia formation. Exposing mice transplanted with CBFbeta-SMMHC-transduced cells to a mutagen, ethylnitrosourea, markedly accelerated leukemogenesis compared to expressing CBFbeta-SMMHC with loss of p16p19, indicating the need for multiple "hits" for transformation. The INV/p16p19 and INV/E7 leukemias were lymphoid and were clonal and retransplantable. Overall, these findings indicate that CBF mutations cooperate with genetic alterations that accelerate G(1) to induce acute leukemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956074

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

2.  Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3.

Authors:  Hong Guo; Alan D Friedman
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

Review 3.  Mouse models for core binding factor leukemia.

Authors:  D W L Chin; N Watanabe-Okochi; C Q Wang; V Tergaonkar; M Osato
Journal:  Leukemia       Date:  2015-07-13       Impact factor: 11.528

4.  Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability.

Authors:  Mark Wunderlich; Ondrej Krejci; Junping Wei; James C Mulloy
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

Review 5.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

6.  Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation.

Authors:  Linsheng Zhang; Florence B Fried; Hong Guo; Alan D Friedman
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113

7.  FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.

Authors:  Hyung-Gyoon Kim; Kyoko Kojima; C Scott Swindle; Claudiu V Cotta; Yongliang Huo; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2007-10-29       Impact factor: 22.113

8.  The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain.

Authors:  Kristie L Durst; Bart Lutterbach; Tanawan Kummalue; Alan D Friedman; Scott W Hiebert
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.